What happened with ZYME today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Pharmaceutical companies pay Zymeworks for access to its drug-design platforms and medicines. Most revenue comes from these partnerships: partners pay for licensing rights and research, then make milestone payments when programs reach agreed development, approval or commercial goals. Approved medicines can also earn Zymeworks royalties linked to sales. Partnerships shift some later-stage development and commercialization costs to partners, while Zymeworks continues developing its own medicines for cancer and inflammatory and autoimmune diseases.
Ziihera, also called zanidatamab, is its only approved medicine and its only source of royalties from product sales. Jazz develops and sells it in most markets, including Japan; BeOne covers Asia excluding Japan, plus Australia and New Zealand. Zymeworks therefore depends on these partners’ development work, regulatory approvals and sales. It retains most Ziihera royalties, but part supports financing from Royalty Pharma until the financing obligations are repaid.
Ziihera is approved for certain patients with HER2-positive biliary tract cancer. Continued approval under its accelerated or conditional authorizations depends on confirmatory trials verifying clinical benefit. Additional uses still require approval, and Zymeworks’ other drug candidates remain in preclinical or clinical development. The company is shifting toward a larger portfolio of royalty-bearing assets to help fund research, rather than relying only on internally developed medicines.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Zymeworks depends on partners’ drug approvals and sales; Daiichi Sankyo, absent from this list, both pays it antibody-license milestones and royalties and competes with Ziihera through Enhertu.
Jazz develops and sells Zymeworks’ cancer medicine Ziihera in territories including the US, Europe and Japan, paying Zymeworks approval milestones and a share of sales. Watch Jazz’s Ziihera net sales: they drove most of Zymeworks’ royalty revenue in 2025.
BeOne develops and sells Zymeworks’ zanidatamab in Asia excluding Japan, plus Australia and New Zealand, paying milestones and sales royalties. Its progress with Ziihera in China matters directly: acceptance and approval of the biliary tract cancer application generated $28 million in milestones for Zymeworks.
Johnson & Johnson licenses Zymeworks’ antibody technology and controls pasritamig’s development and eventual medicine sales, so Zymeworks’ milestones and potential royalties depend on its execution. Watch pasritamig’s Phase 3 trials in castration-resistant prostate cancer; entry into a Phase 3 trial already triggered a $25 million payment.
Xencor competes with Zymeworks in engineering antibodies that bind multiple targets and licensing technologies or drug candidates to pharmaceutical partners. Xencor’s upfront fees, milestones and royalties show the same partner-funded business model as Zymeworks’ antibody platforms.
Genmab’s Rina-S competes with Zymeworks’ ZW191 for cancers expressing FRα, while both companies earn partner payments from licensed antibody innovations. Watch Rina-S’s development as a competing antibody that delivers a drug to FRα-expressing tumors.
AstraZeneca competes with Zymeworks through its Enhertu alliance in HER2-targeted cancer treatment and through AZD5335 against ZW191 in FRα-targeted treatment. Watch its separately reported Enhertu alliance revenue and AZD5335’s development, rather than treating Enhertu as an ordinary AstraZeneca medicine-sales line.
Royalty Pharma competes with Zymeworks to buy rights to drug-sales income, but also lent $250 million to a subsidiary backed by 30% of Zymeworks’ future Ziihera royalties. Zymeworks keeps 70% of those royalties and all earned approval and commercial milestones, with full royalty rights returning after the loan and other amounts due are repaid.
GSK uses Zymeworks’ Azymetric and EFECT antibody technologies to develop medicines, paying license fees and milestones with potential sales royalties; GSK controls and funds the Azymetric products’ development. Watch those products’ progress, not GSK’s overall medicine and vaccine sales: the 2015 collaboration had produced no development or commercial milestones or royalties by December 31, 2025.
Merck pays for access to Zymeworks’ multispecific antibody technology through a license that can generate milestones and sales royalties for human- and animal-health products, but it also competes with Zymeworks. Watch its DLL3-targeted cancer candidate gocatamig, a rival to Zymeworks’ ZW209.
Bristol Myers Squibb licenses Zymeworks’ Azymetric and EFECT antibody technologies and controls the licensed medicines’ development and sales, which can pay Zymeworks milestones and royalties. Its program decisions matter: after excluding a program it stopped in 2023, Zymeworks’ remaining milestone eligibility was $156.5 million at December 31, 2025.
Amgen’s approved cancer medicine IMDELLTRA competes with Zymeworks’ ZW209 and gives it an existing treatment benchmark for targeting DLL3. IMDELLTRA’s treatment results are the concrete comparison to watch as ZW209 develops for DLL3-expressing solid tumors.
AbbVie’s approved cancer medicine Elahere and experimental FRα-targeted antibody-drug conjugates compete with Zymeworks’ ZW191. Watch Elahere’s efficacy and safety and the development of IMGN151 and ABBV901: they set comparisons for ZW191 in FRα-expressing solid tumors.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report may show whether it is advancing programs that use Zymeworks’ antibody technologies, progress that can lead to milestone payments.
Look for disclosed progress in the licensed programs and whether any milestone payment was triggered. Advancing programs that generate payments would show the license can produce revenue; stalled or discontinued programs would leave potential payments unrealized.
ABBVIE INC. earningsABBV
AbbVie’s report offers efficacy, safety and development benchmarks for its FRα-targeted drugs, helping readers assess the competition facing Zymeworks’ ZW191.
Read reported efficacy and safety for Elahere alongside development updates on IMGN151 and ABBV-901. Strong performance from the approved drug and progress in the pipeline would raise the competitive bar for ZW191; weaker evidence or setbacks would soften that comparison, but would not prove ZW191 works.
AstraZeneca PLC earningsAZN
AstraZeneca’s report will show changes in Enhertu alliance revenue, offering a commercial benchmark for HER2-targeted cancer treatments.
Look at AstraZeneca’s separately reported Enhertu alliance revenue, not as an ordinary medicine-sales line. Growth would show stronger commercial traction for this HER2-targeted treatment and provide a benchmark for Ziihera’s competitive landscape; weaker revenue would signal less momentum, but sales in different cancers do not establish demand for Ziihera.
Amgen Inc earningsAMGN
Amgen’s report offers a treatment benchmark from its approved DLL3-targeted drug IMDELLTRA for assessing the competition facing ZW209.
Look for reported treatment results for IMDELLTRA. Strong results would raise the competitive bar for ZW209; weaker results would make that benchmark less formidable, but would not show whether ZW209 works.
Jazz Pharmaceuticals, Inc. earningsJAZZ
Jazz Pharmaceuticals’ report will show Ziihera sales in its territories, which generate royalties for Zymeworks.
Focus on Jazz Pharmaceuticals’ reported Ziihera net sales. Growth would increase the sales-based royalties Zymeworks receives from those territories; weaker sales would reduce that income and put pressure on a key source of product-sales-related revenue.
Zymeworks Inc. earningsThis company
Zymeworks’ report will show how much of its revenue comes from Ziihera royalties and how much still depends on one-off partner payments.
Read royalties from Ziihera sales alongside milestone and other collaboration revenue, then check how much cash operations used. Rising royalties with cash use kept in check would point to a more repeatable revenue base; revenue still led by one-off payments alongside continued cash use would show that the shift is not yet established.
